Nektar Therapeutics vs Tango Therapeutics
Nektar Therapeutics and Tango Therapeutics are similar in size: $55.2m and $62.4m of revenue in their latest fiscal years. Tango Therapeutics grew faster (48.3% against -43.9%). Tango Therapeutics kept more of each dollar of sales as profit: a net margin of -162.9% against -297.1%.
| Latest fiscal year | Nektar TherapeuticsNKTR, 2025 | Tango TherapeuticsTNGX, 2025 |
|---|---|---|
| Revenue | $55.2m | $62.4m |
| Revenue growth | -43.9% | 48.3% |
| Net income | −$164m | −$102m |
| Operating margin | -253.7% | — |
| Net margin | -297.1% | -162.9% |
| Return on equity | — | -37.2% |
| Free cash flow | −$209m | −$140m |
| Cash | $15.1m | $112m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 63 | 137 |
| Market value | $765m | $3.95bn |
| Price vs our value range | — | — |
| Moat score | 18 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 25 sales |